LA JOLLA, CA - GRI Bio, Inc. (NASDAQ: GRI), a biotech firm focused on inflammatory and fibrotic diseases, has shared new preclinical data highlighting the potential of its lead drug candidate GRI ...
Investors are the main target audience for DJSI, while the primary stakeholders of a GRI report are determined by the material issues for the business and typically include shareholders, employees, ...
Our reports adhere to global reporting standards and best practices. Collectively, the World Bank Sustainability Review, Global Reporting Initiative (GRI) Index, Annual Report, Climate-related ...
GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on ...
Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the Earnings Calendar to see dates for upcoming earnings announcements.
LA JOLLA, CA, Oct. 24, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT ...
GRI Bio, Inc. LA JOLLA, CA, Oct. 21, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural ...
The 2023 ESG Report, Star Bulk's sixth annual publication, offers a comprehensive overview of the company's sustainability strategy, performance, and targets. Guided by its ESG Committee, Star Bulk ...
Berry's early reports only included GRI, while SASB soon emerged with some differences "but mainly overlap," he said. In 2021, the company added TCFD for the first time. "We also quite frankly ...